With evolving standards for handling hazardous drugs, nurses must comply with safety and handling guidelines.

The most powerful thing we offer is not a medication or a skill: it’s presence. Presence steadies a hand during uncertainty ...

Coiro, an advanced practice nurse practitioner at the John Theurer Cancer Center at Hackensack University Medical Center Stem ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

Kristin Daly, MSN, ANP-BC, AOCNP, shares advice for preparing patients for possible adverse effects outside of clinic hours.

Standard treatments recommended by NCCN Guidelines for this setting include fruquintinib (Fruzaqla), regorafenib (Stivarga), ...

The multi-day nature of standard chemotherapy regimens used in extensive-stage small cell lung cancer (ES-SCLC) creates ...

Luspatercept-aamt (Reblozyl) is among National Comprehensive Cancer Network Guideline recommendations for low-risk MDS.

Biomarker testing for patients with ovarian cancer should be completed both in the upfront setting and through disease ...

The FDA has granted approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced or metastatic, ...

The addition of atezolizumab to BCG did not yield improved EFS compared with BCG alone in patients with high-risk non–muscle-invasive bladder cancer.

The FDA has approved durvalumab plus FLOT for the treatment of patients with resectable gastric or gastroesophageal junction adenocarcinoma. The FDA has approved the combination of durvalumab (Imfinzi ...